NO309704B1 - Anvendelse av <omega>-3-fettsyrer for fremstilling av et medisinsk preparat for behandling eller for forhindring av utvikling av disseminert, intravaskulær koagulasjon (DIC) - Google Patents

Anvendelse av <omega>-3-fettsyrer for fremstilling av et medisinsk preparat for behandling eller for forhindring av utvikling av disseminert, intravaskulær koagulasjon (DIC) Download PDF

Info

Publication number
NO309704B1
NO309704B1 NO943102A NO943102A NO309704B1 NO 309704 B1 NO309704 B1 NO 309704B1 NO 943102 A NO943102 A NO 943102A NO 943102 A NO943102 A NO 943102A NO 309704 B1 NO309704 B1 NO 309704B1
Authority
NO
Norway
Prior art keywords
fatty acids
dic
emulsion
treatment
dose
Prior art date
Application number
NO943102A
Other languages
English (en)
Norwegian (no)
Other versions
NO943102L (no
NO943102D0 (no
Inventor
Nils Egberg
Carin Larsson-Backstroem
Jan Jakobsson
Rolf Lundh
Original Assignee
Fresenius Kabi Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fresenius Kabi Ab filed Critical Fresenius Kabi Ab
Publication of NO943102D0 publication Critical patent/NO943102D0/no
Publication of NO943102L publication Critical patent/NO943102L/no
Publication of NO309704B1 publication Critical patent/NO309704B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/60Fish, e.g. seahorses; Fish eggs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/55Linaceae (Flax family), e.g. Linum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO943102A 1992-02-24 1994-08-23 Anvendelse av <omega>-3-fettsyrer for fremstilling av et medisinsk preparat for behandling eller for forhindring av utvikling av disseminert, intravaskulær koagulasjon (DIC) NO309704B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9200541A SE9200541D0 (sv) 1992-02-24 1992-02-24 New usee of omega-3-fatty acids
PCT/SE1993/000146 WO1993016691A1 (en) 1992-02-24 1993-02-23 New use of omega-3-fatty acids

Publications (3)

Publication Number Publication Date
NO943102D0 NO943102D0 (no) 1994-08-23
NO943102L NO943102L (no) 1994-10-21
NO309704B1 true NO309704B1 (no) 2001-03-19

Family

ID=20385410

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943102A NO309704B1 (no) 1992-02-24 1994-08-23 Anvendelse av <omega>-3-fettsyrer for fremstilling av et medisinsk preparat for behandling eller for forhindring av utvikling av disseminert, intravaskulær koagulasjon (DIC)

Country Status (13)

Country Link
US (2) US5747533A (ja)
EP (1) EP0627918B1 (ja)
JP (1) JP3559280B2 (ja)
AT (1) ATE207744T1 (ja)
AU (1) AU671438B2 (ja)
CA (1) CA2117535A1 (ja)
DE (1) DE69331051T2 (ja)
DK (1) DK0627918T3 (ja)
ES (1) ES2162620T3 (ja)
NO (1) NO309704B1 (ja)
SE (1) SE9200541D0 (ja)
SG (1) SG46238A1 (ja)
WO (1) WO1993016691A1 (ja)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0987176A (ja) * 1995-09-26 1997-03-31 Shiseido Co Ltd 糸球体腎炎抑制剤
WO1998057628A1 (fr) * 1997-06-16 1998-12-23 Nippon Suisan Kaisha, Ltd. Composition capable de supprimer le facteur de risque pendant l'exercice
EP0948963B1 (en) * 1998-01-21 2003-05-07 Fideline Pig appeasing pheromones to decrease stress, anxiety and aggressiveness
US6054481A (en) * 1998-01-21 2000-04-25 Fideline Pig appeasing pheromones for enhancing weight gain in a mammal
JP4754688B2 (ja) * 1998-01-21 2011-08-24 フィドゥラン ストレス、不安及び攻撃性を低減するブタ鎮静フェロモン
AU784123B2 (en) * 1999-10-13 2006-02-09 Marco A. Chacon Therapeutic intervention to mimic the effect of caloric restriction
FR2804023B1 (fr) * 2000-01-26 2002-09-20 Johnson & Johnson Consumer Fr Complement nutritionnel a base d'huile de pepins de cassis
JP2004527501A (ja) * 2001-03-05 2004-09-09 ピー. アーネスト,スティーヴン 経腸処方
US8729124B2 (en) * 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
US7323206B1 (en) 2003-03-04 2008-01-29 B. Braun Medical Inc. Reagents and methods for all-in-one total parenteral nutrition for neonates and infants
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
WO2006036969A2 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Formation of barrier layer
WO2006036982A2 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Drug delivery coating for use with a stent
US20060135610A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
ZA200800251B (en) * 2005-06-24 2009-04-29 Drugrecure Aps Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory track
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
JP2009525992A (ja) * 2006-02-10 2009-07-16 スポーツコム デンマーク アプス コーティングを施した錠剤、その製造方法、及び関連する使用
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
WO2008057328A2 (en) 2006-11-06 2008-05-15 Atrium Medical Corporation Tissue separating device with reinforced support for anchoring mechanisms
US20080207756A1 (en) * 2007-02-27 2008-08-28 Atrium Medical Corporation Bio-absorbable oil suspension
CA2692394A1 (en) * 2007-07-06 2009-01-15 Seth J. Baum Fatty acid compositions and methods of use
ES2748136T3 (es) 2007-10-15 2020-03-13 United Animal Health Inc Método para aumentar el rendimiento de las crías
CA2704371A1 (en) * 2007-11-01 2009-05-07 Wake Forest University School Of Medicine Compositions and methods for prevention and treatment of mammalian diseases
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
US20100323028A1 (en) * 2007-11-30 2010-12-23 Jbs United, Inc. Method and composition for treating pulmonary hemorrhage
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
US20110045050A1 (en) * 2009-08-24 2011-02-24 Atrium Medical Corporation Nanoemulsion formulations for direct delivery
US20110206741A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation DHA Triglyceride Emulsions
WO2011103512A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha free fatty acid emulsions
WO2012009707A2 (en) 2010-07-16 2012-01-19 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
US20210176999A1 (en) 2011-04-17 2021-06-17 Omega Foods, LLC Prepared foods having high efficacy omega-6/omega-3 balanced polyunsaturated fatty acids
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
US9216199B2 (en) 2013-12-05 2015-12-22 Buriva, LLC Nutritional supplement containing phospholipid-DHA derived from eggs
US9549937B2 (en) 2013-12-05 2017-01-24 Burvia, LLC. Composition containing phospholipid-DHA and folate
US9610302B2 (en) 2013-12-05 2017-04-04 Buriva, LLC. Composition containing phospholipid-DHA and B vitamins
US9233114B2 (en) 2013-12-05 2016-01-12 Buriva, LLC Dietary supplement containing phospholipid-DHA derived from eggs
US10183044B2 (en) * 2015-05-15 2019-01-22 P Tech, Llc Systems and methods for thrombosis prevention
US9655847B1 (en) * 2016-07-18 2017-05-23 National Guard Health Affairs Therapeutic liposome and method of treating a subject having cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752618A (en) * 1984-07-12 1988-06-21 New England Deaconess Hospital Method of minimizing efects of infection through diet
US4678808A (en) * 1985-10-15 1987-07-07 Baxter Travenol Laboratories, Inc. Rapid acting intravenous emulsions of omega-3 fatty acid esters
WO1988001861A1 (en) * 1986-09-17 1988-03-24 Baxter Travenol Laboratories, Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic, vascular, cardiovascular, and/or thrombotic diseases
DE3719097C1 (de) * 1987-06-06 1988-06-09 Fratzer Uwe Arzneimittel,enthaltend Eicosapentaensaeure und Docosahexaensaeure als ungesaettigte Fettsaeuren sowie Vitamin E
GB8729751D0 (en) * 1987-12-21 1988-02-03 Norsk Hydro As Feed additive & feed containing such additive
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5223285A (en) * 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients

Also Published As

Publication number Publication date
ES2162620T3 (es) 2002-01-01
SG46238A1 (en) 1998-02-20
ATE207744T1 (de) 2001-11-15
SE9200541D0 (sv) 1992-02-24
EP0627918A1 (en) 1994-12-14
US5747533A (en) 1998-05-05
DE69331051D1 (de) 2001-12-06
JPH07507766A (ja) 1995-08-31
EP0627918B1 (en) 2001-10-31
AU3652993A (en) 1993-09-13
JP3559280B2 (ja) 2004-08-25
CA2117535A1 (en) 1993-09-02
DK0627918T3 (da) 2002-01-14
WO1993016691A1 (en) 1993-09-02
NO943102L (no) 1994-10-21
US5731346A (en) 1998-03-24
DE69331051T2 (de) 2002-06-13
AU671438B2 (en) 1996-08-29
NO943102D0 (no) 1994-08-23

Similar Documents

Publication Publication Date Title
NO309704B1 (no) Anvendelse av &lt;omega&gt;-3-fettsyrer for fremstilling av et medisinsk preparat for behandling eller for forhindring av utvikling av disseminert, intravaskulær koagulasjon (DIC)
Anez‐Bustillos et al. Intravenous fat emulsion formulations for the adult and pediatric patient: understanding the differences
Jain et al. Omega-3 fatty acids and cardiovascular disease
Vanschoonbeek et al. Fish oil consumption and reduction of arterial disease
Waitzberg et al. New parenteral lipid emulsions for clinical use
Hornstra Dietary fats and arterial thrombosis
DeCaterina et al. Vascular prostacyclin is increased in patients ingesting omega-3 polyunsaturated fatty acids before coronary artery bypass graft surgery.
Mehta et al. Dietary supplementation with omega-3 polyunsaturated fatty acids in patients with stable coronary heart disease: effects on indices of platelet and neutrophil function and exercise performance
McCann et al. Aspirin and dipyridamole decrease intimal hyperplasia in experimental vein grafts.
Matata et al. Cardiopulmonary bypass exacerbates oxidative stress but does not increase proinflammatory cytokine release in patients with diabetes compared with patients without diabetes: regulatory effects of exogenous nitric oxide
Carrel et al. Aprotinin in pediatric cardiac operations: a benefit in complex malformations and with high-dose regimen only
US20070197644A1 (en) Use of 13-HODE as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
JPH08507531A (ja) 進行性組織壊死、再潅流損傷、細菌転座及び成人呼吸困難症候群の予防法
McClaskey et al. Subdural hematoma after a fall in an elderly patient taking high‐dose omega‐3 fatty acids with warfarin and aspirin: case report and review of the literature
Owren Coronary thrombosis: its mechanism and possible prevention by linolenic acid
Mundi et al. Emergence of mixed‐oil fat emulsions for use in parenteral nutrition
Gong et al. Aspirin enhances protective effect of fish oil against thrombosis and injury‐induced vascular remodelling
Boisrame-Helms et al. Lipid emulsions for parenteral nutrition in critical illness
Kılıcoglu et al. The ultrastructural research of liver in experimental obstructive jaundice and effect of honey
Bayorh et al. Effect of palm oil on blood pressure, endothelial function and oxidative stress
Jeremy et al. Cigarette smoking and cardiovascular disease
Svaneborg et al. The acute and short-time effect of supplementation with the combination of n− 3 fatty acids and acetylsalicylic acid on platelet function and plasma lipids
Hamazaki et al. The safety of fish oils for those whose risk of injury is high
Calder Lipids and the critically ill patient
Bilku et al. Can enhanced recovery programmes be further improved by the addition of omega three fatty acids?

Legal Events

Date Code Title Description
MK1K Patent expired